Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Gilead Sciences Inc Drug Patent Portfolio

Gilead Sciences Inc owns 18 orange book drugs protected by 168 US patents with Tybost having the least patent protection, holding only 4 patents. And Stribild with maximum patent protection, holding 35 patents. Given below is the list of Gilead Sciences Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11491169 Remdesivir treatment methods 28 Nov, 2041
Active
US11903953 Remdesivir treatment methods 28 Nov, 2041
Active
US11975012 Remdesivir treatment methods 28 Nov, 2041
Active
US11944611 Capsid inhibitors for the treatment of HIV 04 Jun, 2041
Active
US11491169 Remdesivir treatment methods 28 May, 2041
Active
US11903953 Remdesivir treatment methods 28 May, 2041
Active
US11975012 Remdesivir treatment methods 28 May, 2041
Active
US10675296 Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections 10 Jan, 2039
Active
US11266681 Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections 10 Jan, 2039
Active
US11975017 Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections 10 Jan, 2039
Active
US11267799 Solid forms of an HIV capsid inhibitor 16 Aug, 2038
Active
US10675296 Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections 10 Jul, 2038
Active
US11266681 Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections 10 Jul, 2038
Active
US11975017 Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections 10 Jul, 2038
Active
US11338007 Combination formulation of three antiviral compounds 01 Dec, 2037
Active
US10071985 Therapeutic compounds 17 Aug, 2037
Active
US10654827 Therapeutic compounds 17 Aug, 2037
Active
US10912814 Combination formulation of three antiviral compounds 01 Jun, 2037
Active
US11338007 Combination formulation of three antiviral compounds 01 Jun, 2037
Active
US10695361 Methods for treating arenaviridae and coronaviridae virus infections 16 Mar, 2037
Active
US11007208 Methods for treating arenaviridae and coronaviridae virus infections 16 Mar, 2037
Active
US11382926 Methods for treating Arenaviridae and Coronaviridae virus infections 16 Mar, 2037
Active
US10548846 Therapeutic compositions for treatment of human immunodeficiency virus 08 Nov, 2036
Active
US11744802 Therapeutic compositions for treatment of human immunodeficiency virus 08 Nov, 2036
Active
US10695361 Methods for treating arenaviridae and coronaviridae virus infections 16 Sep, 2036
Active
US11007208 Methods for treating arenaviridae and coronaviridae virus infections 16 Sep, 2036
Active
US11382926 Methods for treating Arenaviridae and Coronaviridae virus infections 16 Sep, 2036
Active
US9724360 Methods for treating Filoviridae virus infections 29 Apr, 2036
Active
US9949994 Methods for treating Filoviridae virus infections 29 Apr, 2036
Active
US9724360 Methods for treating Filoviridae virus infections 29 Oct, 2035
Active
US9949994 Methods for treating Filoviridae virus infections 29 Oct, 2035
Active
US10385067 Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate 19 Jun, 2035
Active
US9708342 Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate 19 Jun, 2035
Active
US10272058 Treatment of intrahepatic cholestatic diseases 19 Mar, 2035
Active
US11406611 Treatment of intrahepatic cholestatic diseases 19 Mar, 2035
Active
US11596614 Treatment of intrahepatic cholestatic diseases 19 Mar, 2035
Active
US9486428 Treatment of intrahepatic cholestatic diseases 19 Mar, 2035
Active
US10086011 Combination formulation of two antiviral compounds 30 Jul, 2034
Active
US11116783 Combination formulation of two antiviral compounds 30 Jul, 2034
Active
US11707479 Combination formulation of two antiviral compounds 30 Jul, 2034
Active
US9757406 Combination formulation of two antiviral compounds 30 Jul, 2034
Active
US10039779 Combination formulation of two antiviral compounds 30 Jul, 2034
Active
US9296782 Inhibitors of hepatitis C virus 17 Jul, 2034
Active
US9951043 Therapeutic compounds 28 Feb, 2034
Active
US10086011 Combination formulation of two antiviral compounds 30 Jan, 2034
Active
US11116783 Combination formulation of two antiviral compounds 30 Jan, 2034
Active
US11707479 Combination formulation of two antiviral compounds 30 Jan, 2034
Active
US9757406 Combination formulation of two antiviral compounds 30 Jan, 2034
Active
US10039779 Combination formulation of two antiviral compounds 30 Jan, 2034
Active
US9216996 Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections 19 Dec, 2033
Active
US9732092 Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections 19 Dec, 2033
Active
US9469643 Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one 02 Sep, 2033
Active
US8575135 Antiviral compounds 16 May, 2033
Active
US8921341 Antiviral compounds 16 May, 2033
Active
US8940718 Antiviral compounds 16 May, 2033
Active
US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Apr, 2033
Active
US9393256 Methods for treating HCV 14 Mar, 2033
Active
US10730879 Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one 05 Mar, 2033
Active
US8865730 Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one 05 Mar, 2033
Active
US8754065 Tenofovir alafenamide hemifumarate 15 Feb, 2033
Active
US9296769 Tenofovir alafenamide hemifumarate 15 Feb, 2033
Active
US10857102 Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate 14 Jan, 2033
Active
US8575135 Antiviral compounds 16 Nov, 2032
Active
US8921341 Antiviral compounds 16 Nov, 2032
Active
US8940718 Antiviral compounds 16 Nov, 2032
Active
US9868745 Antiviral compounds 16 Nov, 2032
Active
US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Oct, 2032
Active
US10456414 Methods for treating HCV 14 Sep, 2032
Active
US9393256 Methods for treating HCV 14 Sep, 2032
Active
US8754065 Tenofovir alafenamide hemifumarate 15 Aug, 2032
Active
US9296769 Tenofovir alafenamide hemifumarate 15 Aug, 2032
Active
US11492353 Methods and compounds for treating Paramyxoviridae virus infections 08 Jun, 2032
Active
US10065958 Methods and compounds for treating Paramyxoviridae virus infections 16 Mar, 2032
Active
US11492353 Methods and compounds for treating Paramyxoviridae virus infections 08 Dec, 2031
Active
US10065958 Methods and compounds for treating Paramyxoviridae virus infections 16 Sep, 2031
Active
US8618076 Nucleoside phosphoramidates 11 Jun, 2031
Active
US9284342 Nucleoside phosphoramidates 13 Mar, 2031
Active
US8618076 Nucleoside phosphoramidates 11 Dec, 2030
Active
US8088368 Antiviral compounds 12 Nov, 2030
Active
US8273341 Antiviral compounds 12 Nov, 2030
Active
US8822430 Antiviral compounds 12 Nov, 2030
Active
US8841278 Antiviral compounds 12 Nov, 2030
Active
US9511056 Antiviral compounds 12 Nov, 2030
Active
US8633219 Combination therapy 30 Oct, 2030
Active
US9284342 Nucleoside phosphoramidates 13 Sep, 2030
Active
US8088368 Antiviral compounds 12 May, 2030
Active
US8273341 Antiviral compounds 12 May, 2030
Active
US8822430 Antiviral compounds 12 May, 2030
Active
US8841278 Antiviral compounds 12 May, 2030
Active
US9511056 Antiviral compounds 12 May, 2030
Active
US8633219 Combination therapy 30 Apr, 2030
Active
US9492449 Therapies for hematologic malignancies 11 Mar, 2030
Active
US8008264 1′-substituted carba-nucleoside analogs for antiviral treatment 06 Mar, 2030
Active
US8148374 Modulators of pharmacokinetic properties of therapeutics 03 Mar, 2030
Active
US9891239 Modulators of pharmacokinetic properties of therapeutics 03 Mar, 2030
Active
US8318682 1′substituted carba-nucleoside analogs for antiviral treatment 22 Oct, 2029
Active
USRE46762 1′-substituted carba-nucleoside analogs for antiviral treatment 22 Oct, 2029
Active
US7964580 NA 26 Sep, 2029
Active
US8633309 Nucleoside phosphoramidates 26 Sep, 2029
Active
US8889159 Compositions and methods for treating hepatitis C virus 26 Sep, 2029
Active
US9549941 Compositions and methods for treating hepatitis C virus 26 Sep, 2029
Active
US8008264 1′-substituted carba-nucleoside analogs for antiviral treatment 06 Sep, 2029
Active
US8148374 Modulators of pharmacokinetic properties of therapeutics 03 Sep, 2029
Active
US9891239 Modulators of pharmacokinetic properties of therapeutics 03 Sep, 2029
Active
US8318682 1′substituted carba-nucleoside analogs for antiviral treatment 22 Apr, 2029
Active
USRE46762 1′-substituted carba-nucleoside analogs for antiviral treatment 22 Apr, 2029
Active
US7964580 NA 26 Mar, 2029
Active
US8633309 Nucleoside phosphoramidates 26 Mar, 2029
Active
US8889159 Compositions and methods for treating hepatitis C virus 26 Mar, 2029
Active
US9549941 Compositions and methods for treating hepatitis C virus 26 Mar, 2029
Active
US8334270 NA 21 Sep, 2028
Active
US8580765 NA 21 Sep, 2028
Active
US8735372 NA 21 Sep, 2028
Active
US9085573 NA 21 Sep, 2028
Active
US8334270 NA 21 Mar, 2028
Active
US8580765 NA 21 Mar, 2028
Active
US8735372 NA 21 Mar, 2028
Active
US9085573 NA 21 Mar, 2028
Active
US8957046 NA 21 Mar, 2028
Active
US9585906 NA 21 Mar, 2028
Active
US7635704 Stable crystal of 4-oxoquinoline compound 26 Apr, 2027
Active
US8981103 Stable crystal of 4-oxoquinoline compound 26 Apr, 2027
Active
US7176220 4-oxoquinoline compound and use thereof as pharmaceutical agent 27 Feb, 2027
Active
US7635704 Stable crystal of 4-oxoquinoline compound 26 Oct, 2026
Active
US8981103 Stable crystal of 4-oxoquinoline compound 26 Oct, 2026
Active
US7709682 Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives 13 Sep, 2026
Active
US7176220 4-oxoquinoline compound and use thereof as pharmaceutical agent 27 Aug, 2026
Active
US8841310 Combinations of a pyrimidine containing NNRTI with RT inhibitors 09 Dec, 2025
Active
US7390791 Prodrugs of phosphonate nucleotide analogues 17 Oct, 2025
Active
USRE44638 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta 05 Aug, 2025
Active
US7301050 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs 02 Aug, 2025
Active
USRE44599 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta 21 Jul, 2025
Active
US8980901 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta 12 May, 2025
Active
US9149477 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta 12 May, 2025
Active
US7125879 HIV inhibiting pyrimidines derivatives 21 Apr, 2025
Active
US7390791 Prodrugs of phosphonate nucleotide analogues 17 Apr, 2025
Active
US8716264 Compositions and methods for combination antiviral therapy 13 Jul, 2024 Expired
US8592397 Compositions and methods for combination antiviral therapy 13 Jan, 2024 Expired
US8716264 Compositions and methods for combination antiviral therapy 13 Jan, 2024 Expired
US9457036 Compositions and methods for combination antiviral therapy 13 Jan, 2024 Expired
US9744181 Compositions and methods for combination antiviral therapy 13 Jan, 2024 Expired
US8080551 HIV inhibiting pyrimidines derivatives 11 Apr, 2023 Expired
US8101629 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile 09 Aug, 2022 Expired
US7803788 Prodrugs of phosphonate nucoleotide analogues 02 Feb, 2022 Expired
US7800788 Upright image processing apparatus with pivotable image reading portion 02 Feb, 2022 Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Sep, 2021 Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 May, 2021 Expired
US6800620 Inhibitors of human phosphatidylinositol 3-kinase delta 24 Apr, 2021 Expired
US6949535 Inhibitors of human phosphatidyl-inositol 3-kinase delta 24 Apr, 2021 Expired
US8138195 Inhibitors of human phosphatidylinositol 3-kinase delta 24 Apr, 2021 Expired
US8492389 Inhibitors of human phosphatidylinositol 3-kinase delta 24 Apr, 2021 Expired
US8637533 Inhibitors of human phosphatidylinositol 3-kinase delta 24 Apr, 2021 Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Mar, 2021 Expired
US6838464 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents 26 Feb, 2021 Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 Nov, 2020 Expired
US7067522 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents 20 Dec, 2019 Expired
US5922695 Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability 25 Jan, 2018 Expired
US5935946 Nucleotide analog composition and synthesis method 25 Jan, 2018 Expired
US5977089 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jan, 2018 Expired
US6043230 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jan, 2018 Expired
US5914331 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jan, 2018 Expired
US5922695 Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability 25 Jul, 2017 Expired
US5935946 Nucleotide analog composition and synthesis method 25 Jul, 2017 Expired
US5977089 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jul, 2017 Expired
US6043230 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jul, 2017 Expired
US5914331 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jul, 2017 Expired
US5814639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Mar, 2016 Expired
US5814639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Sep, 2015 Expired


Given below is the list of recent legal activities going on the following drug patents of Gilead Sciences Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 10 Jul, 2024 US9549941
Electronic Review
Critical
07 Jun, 2024 US11944611
Payment of Maintenance Fee, 12th Year, Large Entity 05 Jun, 2024 US8334270
Payment of Maintenance Fee, 12th Year, Large Entity 05 Jun, 2024 US8334270
Petition Entered 30 May, 2024 US11944611
Payment of Maintenance Fee, 4th Year, Large Entity 22 May, 2024 US10857102
Payment of Maintenance Fee, 8th Year, Large Entity 22 May, 2024 US9511056
Payment of Maintenance Fee, 12th Year, Large Entity 15 May, 2024 US8318682
Second letter to regulating agency to determine regulatory review period 10 May, 2024 US9951043
Payment of Maintenance Fee, 8th Year, Large Entity 01 May, 2024 US9492449
Expire Patent
Critical
22 Apr, 2024 US8138195
Payment of Maintenance Fee, 8th Year, Large Entity 03 Apr, 2024 US9469643
Recordation of Patent Grant Mailed
Critical
02 Apr, 2024 US11944611
Recordation of Patent eGrant 02 Apr, 2024 US11944611
Email Notification
Critical
02 Apr, 2024 US11944611


Gilead Sciences Inc's Drug Patent Litigations

Gilead Sciences Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 05, 2001, against patent number US6642245. The petitioner , challenged the validity of this patent, with DIONNE as the respondent. Click below to track the latest information on how companies are challenging Gilead Sciences Inc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8889159 December, 2017 Terminated-Denied
(19 Jul, 2018)
Gilead Pharmasset LLC Initiative for Medicines, Access & Knowledge (I-MAK), Inc.
US9393256 December, 2017 Terminated-Denied
(20 Jun, 2018)
Gilead Pharmasset LLC Initiative for Medicines, Access & Knowledge (I-MAK), Inc.
US8735372 November, 2017 Institution Denied
(13 Jun, 2018)
Gilead Pharmasset LLC et al. Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al.
US8633309 October, 2017 Institution Denied
(24 May, 2018)
Gilead Pharmasset LLC Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al.
US9284342 November, 2017 Institution Denied
(24 May, 2018)
Gilead Pharmasset LLC Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al.
US8334270 October, 2017 Institution Denied
(21 May, 2018)
Gilead Pharmasset LLC et al. Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al.
US7964580 October, 2017 Institution Denied
(04 May, 2018)
Gilead Pharmasset LLC et al. Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al.
US9891239 August, 2013 Decision
(20 Jul, 2016)
Manoj C. Desai et al
US5935946 June, 2014 Terminated-Denied
(17 Dec, 2014)
Gilead Sciences, Inc. MYLAN PHARMACEUTICALS INC.
US5922695 June, 2014 Terminated-Denied
(09 Dec, 2014)
Gilead Sciences, Inc. Mylan Pharmaceuticals Inc.
US5977089 June, 2014 Terminated-Denied
(09 Dec, 2014)
Gilead Sciences, Inc. Mylan Pharmaceuticals Inc.
US6043230 June, 2014 Terminated-Denied
(09 Dec, 2014)
Gilead Sciences, Inc. Mylan Pharmaceuticals Inc.
US8633219 August, 2011 Decision
(19 Jul, 2012)
Yuji Matsuzaki et al
US6703396 April, 2002 Decision
(04 Apr, 2002)
DIONNE
US6642245 July, 2001 Decision
(05 Jul, 2001)
DIONNE


Gilead Sciences Inc Drug Patents' Oppositions Filed in EPO

Gilead Sciences Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 13, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04701819A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP16180589A Oct, 2020 Cooke, Richard Granted and Under Opposition
EP16180589A Oct, 2020 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP16798063A May, 2020 Sandoz GmbH Granted and Under Opposition
EP16798063A May, 2020 Cooke, Richard Granted and Under Opposition
EP16798063A May, 2020 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP16180589A Jan, 2020 STADA Arzneimittel AG Granted and Under Opposition
EP15739063A Oct, 2018 Cooke, Richard Revoked
EP12768967A Aug, 2018 Gillard, Richard Edward Patent maintained as amended
EP13164300A Jan, 2018 Georg Kalhammer/Stephan Teipel Granted and Under Opposition
EP13164300A Jan, 2018 Aechter, Bernd Granted and Under Opposition
EP13164300A Jan, 2018 Cooke, Richard Granted and Under Opposition
EP12753867A Jul, 2017 FRKelly Granted and Under Opposition
EP12753867A Jul, 2017 Sandoz GmbH Granted and Under Opposition
EP12753867A Jul, 2017 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP05752122A Jun, 2017 STADA Arzneimittel AG Opposition rejected
EP12167590A May, 2017 Cooke, Richard Revoked
EP12167591A May, 2017 Cooke, Richard Revoked
EP12167590A May, 2017 Teva Pharmaceutical Industries LTD. Revoked
EP12167591A May, 2017 Teva Pharmaceutical Industries LTD. Revoked
EP12167589A May, 2017 Cooke, Richard Granted and Under Opposition
EP12167589A May, 2017 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP12167596A Apr, 2017 Cooke, Richard Revoked
EP12167596A Apr, 2017 Teva Pharmaceutical Industries Ltd Revoked
EP09739981A Jun, 2016 Cooke, Richard Revoked
EP09739981A Jun, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP10703766A Apr, 2016 Cooke, Richard Revoked
EP10703766A Apr, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP07836007A Mar, 2016 Trösch, Dominique Granted and Under Opposition
EP07836007A Mar, 2016 Georg Kalhammer/Stephan Teipel Granted and Under Opposition
EP07836007A Mar, 2016 Teva Pharmaceutical Industries LTD. Granted and Under Opposition
EP04787096A Jan, 2016 Page White & Farrer Limited Patent maintained as amended
EP01961695A Nov, 2015 HEXAL PHARMA AG Patent maintained as amended
EP01961695A Nov, 2015 Strawman Limited Patent maintained as amended
EP01961695A Nov, 2015 Swindell & Pearson Limited Patent maintained as amended
EP01961695A Nov, 2015 Teva Pharmaceutical Industries Ltd Patent maintained as amended
EP11791161A Jun, 2015 HGF Limited Patent maintained as amended
EP11791161A Jun, 2015 LEK Pharmaceuticals d.d. Patent maintained as amended
EP08732818A Feb, 2015 Intellectual Property Services (IPS) Granted and Under Opposition
EP08732818A Feb, 2015 STADA Arzneimittel AG Granted and Under Opposition
EP08732818A Feb, 2015 Actavis Group PTC ehf Granted and Under Opposition
EP08732818A Feb, 2015 ZBM Patents - Zea, Barlocci & Markvardsen Granted and Under Opposition
EP08732818A Feb, 2015 Pharmaceutical Works POLPHARMA Granted and Under Opposition
EP08732818A Feb, 2015 Generics [UK] Ltd (trading as Mylan) Granted and Under Opposition
EP08732818A Feb, 2015 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP08732818A Feb, 2015 Fleischer, Holm Herbert Granted and Under Opposition
EP08732818A Feb, 2015 ELLIS IP LTD Granted and Under Opposition
EP08732818A Feb, 2015 MEDECINS DU MONDE Granted and Under Opposition
EP05108086A Feb, 2012 Hamm, Volker The patent has been limited
EP04701819A Mar, 2009 Generics [UK] Limited Revoked
EP04701819A Mar, 2009 Teva Pharmaceutical Industries LTD. Revoked


Gilead Sciences Inc's Family Patents

Gilead Sciences Inc drugs have patent protection in a total of 65 countries. It's US patent count contributes only to 15.0% of its total global patent coverage. 8 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Gilead Sciences Inc Drug List

Given below is the complete list of Gilead Sciences Inc's drugs and the patents protecting them.


1. Biktarvy

Biktarvy is protected by 15 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10548846 Therapeutic compositions for treatment of human immunodeficiency virus 08 Nov, 2036
(11 years from now)
Active
US11744802 Therapeutic compositions for treatment of human immunodeficiency virus 08 Nov, 2036
(11 years from now)
Active
US10385067 Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate 19 Jun, 2035
(10 years from now)
Active
US9708342 Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate 19 Jun, 2035
(10 years from now)
Active
US9216996 Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections 19 Dec, 2033
(9 years from now)
Active
US9732092 Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections 19 Dec, 2033
(9 years from now)
Active
US8754065
(Pediatric)
Tenofovir alafenamide hemifumarate 15 Feb, 2033
(8 years from now)
Active
US9296769
(Pediatric)
Tenofovir alafenamide hemifumarate 15 Feb, 2033
(8 years from now)
Active
US8754065 Tenofovir alafenamide hemifumarate 15 Aug, 2032
(7 years from now)
Active
US9296769 Tenofovir alafenamide hemifumarate 15 Aug, 2032
(7 years from now)
Active
US7390791
(Pediatric)
Prodrugs of phosphonate nucleotide analogues 17 Oct, 2025
(10 months from now)
Active
US7390791 Prodrugs of phosphonate nucleotide analogues 17 Apr, 2025
(4 months from now)
Active
US7803788 Prodrugs of phosphonate nucoleotide analogues 02 Feb, 2022
(2 years ago)
Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Mar, 2021
(3 years ago)
Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 Nov, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Biktarvy's drug page


2. Complera

Complera is protected by 28 patents, out of which 25 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10857102 Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate 14 Jan, 2033
(8 years from now)
Active
US8841310 Combinations of a pyrimidine containing NNRTI with RT inhibitors 09 Dec, 2025
(1 year, 23 days from now)
Active
US7125879 HIV inhibiting pyrimidines derivatives 21 Apr, 2025
(5 months from now)
Active
US8716264
(Pediatric)
Compositions and methods for combination antiviral therapy 13 Jul, 2024
(4 months ago)
Expired
US8592397 Compositions and methods for combination antiviral therapy 13 Jan, 2024
(10 months ago)
Expired
US8716264 Compositions and methods for combination antiviral therapy 13 Jan, 2024
(10 months ago)
Expired
US9457036 Compositions and methods for combination antiviral therapy 13 Jan, 2024
(10 months ago)
Expired
US9744181 Compositions and methods for combination antiviral therapy 13 Jan, 2024
(10 months ago)
Expired
US8080551 HIV inhibiting pyrimidines derivatives 11 Apr, 2023
(1 year, 7 months ago)
Expired
US8101629 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile 09 Aug, 2022
(2 years ago)
Expired
US6703396
(Pediatric)
Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Sep, 2021
(3 years ago)
Expired
US6642245
(Pediatric)
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 May, 2021
(3 years ago)
Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Mar, 2021
(3 years ago)
Expired
US6838464 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents 26 Feb, 2021
(3 years ago)
Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 Nov, 2020
(4 years ago)
Expired
US7067522 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents 20 Dec, 2019
(4 years ago)
Expired
US5922695
(Pediatric)
Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability 25 Jan, 2018
(6 years ago)
Expired
US5935946
(Pediatric)
Nucleotide analog composition and synthesis method 25 Jan, 2018
(6 years ago)
Expired
US5977089
(Pediatric)
Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jan, 2018
(6 years ago)
Expired
US6043230
(Pediatric)
Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jan, 2018
(6 years ago)
Expired
US5914331
(Pediatric)
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jan, 2018
(6 years ago)
Expired
US5922695 Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability 25 Jul, 2017
(7 years ago)
Expired
US5935946 Nucleotide analog composition and synthesis method 25 Jul, 2017
(7 years ago)
Expired
US5977089 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jul, 2017
(7 years ago)
Expired
US6043230 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jul, 2017
(7 years ago)
Expired
US5914331 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jul, 2017
(7 years ago)
Expired
US5814639
(Pediatric)
Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Mar, 2016
(8 years ago)
Expired
US5814639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Sep, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Complera's drug page


3. Descovy

Descovy is protected by 15 patents, out of which 9 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8754065
(Pediatric)
Tenofovir alafenamide hemifumarate 15 Feb, 2033
(8 years from now)
Active
US9296769
(Pediatric)
Tenofovir alafenamide hemifumarate 15 Feb, 2033
(8 years from now)
Active
US8754065 Tenofovir alafenamide hemifumarate 15 Aug, 2032
(7 years from now)
Active
US9296769 Tenofovir alafenamide hemifumarate 15 Aug, 2032
(7 years from now)
Active
US7390791
(Pediatric)
Prodrugs of phosphonate nucleotide analogues 17 Oct, 2025
(10 months from now)
Active
US7390791 Prodrugs of phosphonate nucleotide analogues 17 Apr, 2025
(4 months from now)
Active
US7803788 Prodrugs of phosphonate nucoleotide analogues 02 Feb, 2022
(2 years ago)
Expired
US6703396
(Pediatric)
Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Sep, 2021
(3 years ago)
Expired
US6642245
(Pediatric)
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 May, 2021
(3 years ago)
Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Mar, 2021
(3 years ago)
Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 Nov, 2020
(4 years ago)
Expired
US5914331
(Pediatric)
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jan, 2018
(6 years ago)
Expired
US5914331 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jul, 2017
(7 years ago)
Expired
US5814639
(Pediatric)
Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Mar, 2016
(8 years ago)
Expired
US5814639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Sep, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Descovy's drug page


4. Epclusa

Epclusa is protected by 32 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10086011
(Pediatric)
Combination formulation of two antiviral compounds 30 Jul, 2034
(9 years from now)
Active
US11116783
(Pediatric)
Combination formulation of two antiviral compounds 30 Jul, 2034
(9 years from now)
Active
US11707479
(Pediatric)
Combination formulation of two antiviral compounds 30 Jul, 2034
(9 years from now)
Active
US9757406
(Pediatric)
Combination formulation of two antiviral compounds 30 Jul, 2034
(9 years from now)
Active
US10086011 Combination formulation of two antiviral compounds 30 Jan, 2034
(9 years from now)
Active
US11116783 Combination formulation of two antiviral compounds 30 Jan, 2034
(9 years from now)
Active
US11707479 Combination formulation of two antiviral compounds 30 Jan, 2034
(9 years from now)
Active
US9757406 Combination formulation of two antiviral compounds 30 Jan, 2034
(9 years from now)
Active
US8575135
(Pediatric)
Antiviral compounds 16 May, 2033
(8 years from now)
Active
US8921341
(Pediatric)
Antiviral compounds 16 May, 2033
(8 years from now)
Active
US8940718
(Pediatric)
Antiviral compounds 16 May, 2033
(8 years from now)
Active
US8575135 Antiviral compounds 16 Nov, 2032
(8 years from now)
Active
US8921341 Antiviral compounds 16 Nov, 2032
(8 years from now)
Active
US8940718 Antiviral compounds 16 Nov, 2032
(8 years from now)
Active
US8618076
(Pediatric)
Nucleoside phosphoramidates 11 Jun, 2031
(6 years from now)
Active
US9284342
(Pediatric)
Nucleoside phosphoramidates 13 Mar, 2031
(6 years from now)
Active
US8618076 Nucleoside phosphoramidates 11 Dec, 2030
(6 years from now)
Active
US9284342 Nucleoside phosphoramidates 13 Sep, 2030
(5 years from now)
Active
US7964580
(Pediatric)
NA 26 Sep, 2029
(4 years from now)
Active
US8633309
(Pediatric)
Nucleoside phosphoramidates 26 Sep, 2029
(4 years from now)
Active
US8889159
(Pediatric)
Compositions and methods for treating hepatitis C virus 26 Sep, 2029
(4 years from now)
Active
US7964580 NA 26 Mar, 2029
(4 years from now)
Active
US8633309 Nucleoside phosphoramidates 26 Mar, 2029
(4 years from now)
Active
US8889159 Compositions and methods for treating hepatitis C virus 26 Mar, 2029
(4 years from now)
Active
US8334270
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US8580765
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US8735372
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US9085573
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US8334270 NA 21 Mar, 2028
(3 years from now)
Active
US8580765 NA 21 Mar, 2028
(3 years from now)
Active
US8735372 NA 21 Mar, 2028
(3 years from now)
Active
US9085573 NA 21 Mar, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epclusa's drug page


5. Genvoya

Genvoya is protected by 30 patents, out of which 10 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039718
(Pediatric)
Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Apr, 2033
(8 years from now)
Active
US8754065
(Pediatric)
Tenofovir alafenamide hemifumarate 15 Feb, 2033
(8 years from now)
Active
US9296769
(Pediatric)
Tenofovir alafenamide hemifumarate 15 Feb, 2033
(8 years from now)
Active
US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Oct, 2032
(7 years from now)
Active
US8754065 Tenofovir alafenamide hemifumarate 15 Aug, 2032
(7 years from now)
Active
US9296769 Tenofovir alafenamide hemifumarate 15 Aug, 2032
(7 years from now)
Active
US8633219
(Pediatric)
Combination therapy 30 Oct, 2030
(5 years from now)
Active
US8633219 Combination therapy 30 Apr, 2030
(5 years from now)
Active
US8148374
(Pediatric)
Modulators of pharmacokinetic properties of therapeutics 03 Mar, 2030
(5 years from now)
Active
US9891239
(Pediatric)
Modulators of pharmacokinetic properties of therapeutics 03 Mar, 2030
(5 years from now)
Active
US8148374 Modulators of pharmacokinetic properties of therapeutics 03 Sep, 2029
(4 years from now)
Active
US9891239 Modulators of pharmacokinetic properties of therapeutics 03 Sep, 2029
(4 years from now)
Active
US7635704
(Pediatric)
Stable crystal of 4-oxoquinoline compound 26 Apr, 2027
(2 years from now)
Active
US8981103
(Pediatric)
Stable crystal of 4-oxoquinoline compound 26 Apr, 2027
(2 years from now)
Active
US7176220
(Pediatric)
4-oxoquinoline compound and use thereof as pharmaceutical agent 27 Feb, 2027
(2 years from now)
Active
US7635704 Stable crystal of 4-oxoquinoline compound 26 Oct, 2026
(1 year, 11 months from now)
Active
US8981103 Stable crystal of 4-oxoquinoline compound 26 Oct, 2026
(1 year, 11 months from now)
Active
US7176220 4-oxoquinoline compound and use thereof as pharmaceutical agent 27 Aug, 2026
(1 year, 9 months from now)
Active
US7390791
(Pediatric)
Prodrugs of phosphonate nucleotide analogues 17 Oct, 2025
(10 months from now)
Active
US7390791 Prodrugs of phosphonate nucleotide analogues 17 Apr, 2025
(4 months from now)
Active
US7800788 Upright image processing apparatus with pivotable image reading portion 02 Feb, 2022
(2 years ago)
Expired
US7803788 Prodrugs of phosphonate nucoleotide analogues 02 Feb, 2022
(2 years ago)
Expired
US6703396
(Pediatric)
Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Sep, 2021
(3 years ago)
Expired
US6642245
(Pediatric)
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 May, 2021
(3 years ago)
Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Mar, 2021
(3 years ago)
Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 Nov, 2020
(4 years ago)
Expired
US5914331
(Pediatric)
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jan, 2018
(6 years ago)
Expired
US5914331 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jul, 2017
(7 years ago)
Expired
US5814639
(Pediatric)
Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Mar, 2016
(8 years ago)
Expired
US5814639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Sep, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Genvoya's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Harvoni

Harvoni is protected by 33 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039779
(Pediatric)
Combination formulation of two antiviral compounds 30 Jul, 2034
(9 years from now)
Active
US10039779 Combination formulation of two antiviral compounds 30 Jan, 2034
(9 years from now)
Active
US9393256
(Pediatric)
Methods for treating HCV 14 Mar, 2033
(8 years from now)
Active
US10456414 Methods for treating HCV 14 Sep, 2032
(7 years from now)
Active
US9393256 Methods for treating HCV 14 Sep, 2032
(7 years from now)
Active
US8618076
(Pediatric)
Nucleoside phosphoramidates 11 Jun, 2031
(6 years from now)
Active
US9284342
(Pediatric)
Nucleoside phosphoramidates 13 Mar, 2031
(6 years from now)
Active
US8618076 Nucleoside phosphoramidates 11 Dec, 2030
(6 years from now)
Active
US8088368
(Pediatric)
Antiviral compounds 12 Nov, 2030
(5 years from now)
Active
US8273341
(Pediatric)
Antiviral compounds 12 Nov, 2030
(5 years from now)
Active
US8822430
(Pediatric)
Antiviral compounds 12 Nov, 2030
(5 years from now)
Active
US8841278
(Pediatric)
Antiviral compounds 12 Nov, 2030
(5 years from now)
Active
US9511056
(Pediatric)
Antiviral compounds 12 Nov, 2030
(5 years from now)
Active
US9284342 Nucleoside phosphoramidates 13 Sep, 2030
(5 years from now)
Active
US8088368 Antiviral compounds 12 May, 2030
(5 years from now)
Active
US8273341 Antiviral compounds 12 May, 2030
(5 years from now)
Active
US8822430 Antiviral compounds 12 May, 2030
(5 years from now)
Active
US8841278 Antiviral compounds 12 May, 2030
(5 years from now)
Active
US9511056 Antiviral compounds 12 May, 2030
(5 years from now)
Active
US7964580
(Pediatric)
NA 26 Sep, 2029
(4 years from now)
Active
US8633309
(Pediatric)
Nucleoside phosphoramidates 26 Sep, 2029
(4 years from now)
Active
US8889159
(Pediatric)
Compositions and methods for treating hepatitis C virus 26 Sep, 2029
(4 years from now)
Active
US7964580 NA 26 Mar, 2029
(4 years from now)
Active
US8633309 Nucleoside phosphoramidates 26 Mar, 2029
(4 years from now)
Active
US8889159 Compositions and methods for treating hepatitis C virus 26 Mar, 2029
(4 years from now)
Active
US8334270
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US8580765
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US8735372
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US9085573
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US8334270 NA 21 Mar, 2028
(3 years from now)
Active
US8580765 NA 21 Mar, 2028
(3 years from now)
Active
US8735372 NA 21 Mar, 2028
(3 years from now)
Active
US9085573 NA 21 Mar, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Harvoni's drug page


7. Livdelzi

Livdelzi is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10272058 Treatment of intrahepatic cholestatic diseases 19 Mar, 2035
(10 years from now)
Active
US11406611 Treatment of intrahepatic cholestatic diseases 19 Mar, 2035
(10 years from now)
Active
US11596614 Treatment of intrahepatic cholestatic diseases 19 Mar, 2035
(10 years from now)
Active
US9486428 Treatment of intrahepatic cholestatic diseases 19 Mar, 2035
(10 years from now)
Active
US7709682 Lysine salts of 4-((phenoxyalkyl)thio)-phenoxyacetic acid derivatives 13 Sep, 2026
(1 year, 9 months from now)
Active
US7301050 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs 02 Aug, 2025
(8 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Livdelzi's drug page


8. Odefsey

Odefsey is protected by 20 patents, out of which 13 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8754065
(Pediatric)
Tenofovir alafenamide hemifumarate 15 Feb, 2033
(8 years from now)
Active
US9296769
(Pediatric)
Tenofovir alafenamide hemifumarate 15 Feb, 2033
(8 years from now)
Active
US8754065 Tenofovir alafenamide hemifumarate 15 Aug, 2032
(7 years from now)
Active
US9296769 Tenofovir alafenamide hemifumarate 15 Aug, 2032
(7 years from now)
Active
US7390791
(Pediatric)
Prodrugs of phosphonate nucleotide analogues 17 Oct, 2025
(10 months from now)
Active
US7125879 HIV inhibiting pyrimidines derivatives 21 Apr, 2025
(5 months from now)
Active
US7390791 Prodrugs of phosphonate nucleotide analogues 17 Apr, 2025
(4 months from now)
Active
US8080551 HIV inhibiting pyrimidines derivatives 11 Apr, 2023
(1 year, 7 months ago)
Expired
US8101629 Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile 09 Aug, 2022
(2 years ago)
Expired
US7803788 Prodrugs of phosphonate nucoleotide analogues 02 Feb, 2022
(2 years ago)
Expired
US6703396
(Pediatric)
Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Sep, 2021
(3 years ago)
Expired
US6642245
(Pediatric)
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 May, 2021
(3 years ago)
Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Mar, 2021
(3 years ago)
Expired
US6838464 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents 26 Feb, 2021
(3 years ago)
Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 Nov, 2020
(4 years ago)
Expired
US7067522 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents 20 Dec, 2019
(4 years ago)
Expired
US5914331
(Pediatric)
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jan, 2018
(6 years ago)
Expired
US5914331 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jul, 2017
(7 years ago)
Expired
US5814639
(Pediatric)
Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Mar, 2016
(8 years ago)
Expired
US5814639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Sep, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Odefsey's drug page


9. Sovaldi

Sovaldi is protected by 18 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8618076
(Pediatric)
Nucleoside phosphoramidates 11 Jun, 2031
(6 years from now)
Active
US9284342
(Pediatric)
Nucleoside phosphoramidates 13 Mar, 2031
(6 years from now)
Active
US8618076 Nucleoside phosphoramidates 11 Dec, 2030
(6 years from now)
Active
US9284342 Nucleoside phosphoramidates 13 Sep, 2030
(5 years from now)
Active
US7964580
(Pediatric)
NA 26 Sep, 2029
(4 years from now)
Active
US8633309
(Pediatric)
Nucleoside phosphoramidates 26 Sep, 2029
(4 years from now)
Active
US8889159
(Pediatric)
Compositions and methods for treating hepatitis C virus 26 Sep, 2029
(4 years from now)
Active
US9549941
(Pediatric)
Compositions and methods for treating hepatitis C virus 26 Sep, 2029
(4 years from now)
Active
US7964580 NA 26 Mar, 2029
(4 years from now)
Active
US8633309 Nucleoside phosphoramidates 26 Mar, 2029
(4 years from now)
Active
US8889159 Compositions and methods for treating hepatitis C virus 26 Mar, 2029
(4 years from now)
Active
US9549941 Compositions and methods for treating hepatitis C virus 26 Mar, 2029
(4 years from now)
Active
US8334270
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US8580765
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US9085573
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US8334270 NA 21 Mar, 2028
(3 years from now)
Active
US8580765 NA 21 Mar, 2028
(3 years from now)
Active
US9085573 NA 21 Mar, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sovaldi's drug page


10. Stribild

Stribild is protected by 35 patents, out of which 21 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039718
(Pediatric)
Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Apr, 2033
(8 years from now)
Active
US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Oct, 2032
(7 years from now)
Active
US8633219
(Pediatric)
Combination therapy 30 Oct, 2030
(5 years from now)
Active
US8633219 Combination therapy 30 Apr, 2030
(5 years from now)
Active
US8148374
(Pediatric)
Modulators of pharmacokinetic properties of therapeutics 03 Mar, 2030
(5 years from now)
Active
US9891239
(Pediatric)
Modulators of pharmacokinetic properties of therapeutics 03 Mar, 2030
(5 years from now)
Active
US8148374 Modulators of pharmacokinetic properties of therapeutics 03 Sep, 2029
(4 years from now)
Active
US9891239 Modulators of pharmacokinetic properties of therapeutics 03 Sep, 2029
(4 years from now)
Active
US7635704
(Pediatric)
Stable crystal of 4-oxoquinoline compound 26 Apr, 2027
(2 years from now)
Active
US8981103
(Pediatric)
Stable crystal of 4-oxoquinoline compound 26 Apr, 2027
(2 years from now)
Active
US7176220
(Pediatric)
4-oxoquinoline compound and use thereof as pharmaceutical agent 27 Feb, 2027
(2 years from now)
Active
US7635704 Stable crystal of 4-oxoquinoline compound 26 Oct, 2026
(1 year, 11 months from now)
Active
US8981103 Stable crystal of 4-oxoquinoline compound 26 Oct, 2026
(1 year, 11 months from now)
Active
US7176220 4-oxoquinoline compound and use thereof as pharmaceutical agent 27 Aug, 2026
(1 year, 9 months from now)
Active
US8716264
(Pediatric)
Compositions and methods for combination antiviral therapy 13 Jul, 2024
(4 months ago)
Expired
US8592397 Compositions and methods for combination antiviral therapy 13 Jan, 2024
(10 months ago)
Expired
US8716264 Compositions and methods for combination antiviral therapy 13 Jan, 2024
(10 months ago)
Expired
US9457036 Compositions and methods for combination antiviral therapy 13 Jan, 2024
(10 months ago)
Expired
US9744181 Compositions and methods for combination antiviral therapy 13 Jan, 2024
(10 months ago)
Expired
US6703396
(Pediatric)
Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Sep, 2021
(3 years ago)
Expired
US6642245
(Pediatric)
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 May, 2021
(3 years ago)
Expired
US6703396 Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers 09 Mar, 2021
(3 years ago)
Expired
US6642245 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 04 Nov, 2020
(4 years ago)
Expired
US5922695
(Pediatric)
Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability 25 Jan, 2018
(6 years ago)
Expired
US5935946
(Pediatric)
Nucleotide analog composition and synthesis method 25 Jan, 2018
(6 years ago)
Expired
US5977089
(Pediatric)
Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jan, 2018
(6 years ago)
Expired
US6043230
(Pediatric)
Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jan, 2018
(6 years ago)
Expired
US5914331
(Pediatric)
Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jan, 2018
(6 years ago)
Expired
US5922695 Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability 25 Jul, 2017
(7 years ago)
Expired
US5935946 Nucleotide analog composition and synthesis method 25 Jul, 2017
(7 years ago)
Expired
US5977089 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jul, 2017
(7 years ago)
Expired
US6043230 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jul, 2017
(7 years ago)
Expired
US5914331 Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane 02 Jul, 2017
(7 years ago)
Expired
US5814639
(Pediatric)
Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Mar, 2016
(8 years ago)
Expired
US5814639 Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds 29 Sep, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Stribild's drug page


11. Sunlenca

Sunlenca is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11944611 Capsid inhibitors for the treatment of HIV 04 Jun, 2041
(16 years from now)
Active
US11267799 Solid forms of an HIV capsid inhibitor 16 Aug, 2038
(13 years from now)
Active
US10071985 Therapeutic compounds 17 Aug, 2037
(12 years from now)
Active
US10654827 Therapeutic compounds 17 Aug, 2037
(12 years from now)
Active
US9951043 Therapeutic compounds 28 Feb, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sunlenca's drug page


12. Tybost

Tybost is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10039718
(Pediatric)
Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Apr, 2033
(8 years from now)
Active
US10039718 Use of solid carrier particles to improve the processability of a pharmaceutical agent 06 Oct, 2032
(7 years from now)
Active
US8148374
(Pediatric)
Modulators of pharmacokinetic properties of therapeutics 03 Mar, 2030
(5 years from now)
Active
US8148374 Modulators of pharmacokinetic properties of therapeutics 03 Sep, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tybost's drug page


13. Veklury

Veklury is protected by 32 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11491169
(Pediatric)
Remdesivir treatment methods 28 Nov, 2041
(17 years from now)
Active
US11903953
(Pediatric)
Remdesivir treatment methods 28 Nov, 2041
(17 years from now)
Active
US11975012
(Pediatric)
Remdesivir treatment methods 28 Nov, 2041
(17 years from now)
Active
US11491169 Remdesivir treatment methods 28 May, 2041
(16 years from now)
Active
US11903953 Remdesivir treatment methods 28 May, 2041
(16 years from now)
Active
US11975012 Remdesivir treatment methods 28 May, 2041
(16 years from now)
Active
US10675296
(Pediatric)
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections 10 Jan, 2039
(14 years from now)
Active
US11266681
(Pediatric)
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections 10 Jan, 2039
(14 years from now)
Active
US11975017
(Pediatric)
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections 10 Jan, 2039
(14 years from now)
Active
US10675296 Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections 10 Jul, 2038
(13 years from now)
Active
US11266681 Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections 10 Jul, 2038
(13 years from now)
Active
US11975017 Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections 10 Jul, 2038
(13 years from now)
Active
US10695361
(Pediatric)
Methods for treating arenaviridae and coronaviridae virus infections 16 Mar, 2037
(12 years from now)
Active
US11007208
(Pediatric)
Methods for treating arenaviridae and coronaviridae virus infections 16 Mar, 2037
(12 years from now)
Active
US11382926
(Pediatric)
Methods for treating Arenaviridae and Coronaviridae virus infections 16 Mar, 2037
(12 years from now)
Active
US10695361 Methods for treating arenaviridae and coronaviridae virus infections 16 Sep, 2036
(11 years from now)
Active
US11007208 Methods for treating arenaviridae and coronaviridae virus infections 16 Sep, 2036
(11 years from now)
Active
US11382926 Methods for treating Arenaviridae and Coronaviridae virus infections 16 Sep, 2036
(11 years from now)
Active
US9724360
(Pediatric)
Methods for treating Filoviridae virus infections 29 Apr, 2036
(11 years from now)
Active
US9949994
(Pediatric)
Methods for treating Filoviridae virus infections 29 Apr, 2036
(11 years from now)
Active
US9724360 Methods for treating Filoviridae virus infections 29 Oct, 2035
(10 years from now)
Active
US9949994 Methods for treating Filoviridae virus infections 29 Oct, 2035
(10 years from now)
Active
US11492353
(Pediatric)
Methods and compounds for treating Paramyxoviridae virus infections 08 Jun, 2032
(7 years from now)
Active
US10065958
(Pediatric)
Methods and compounds for treating Paramyxoviridae virus infections 16 Mar, 2032
(7 years from now)
Active
US11492353 Methods and compounds for treating Paramyxoviridae virus infections 08 Dec, 2031
(7 years from now)
Active
US10065958 Methods and compounds for treating Paramyxoviridae virus infections 16 Sep, 2031
(6 years from now)
Active
US8008264
(Pediatric)
1′-substituted carba-nucleoside analogs for antiviral treatment 06 Mar, 2030
(5 years from now)
Active
US8318682
(Pediatric)
1′substituted carba-nucleoside analogs for antiviral treatment 22 Oct, 2029
(4 years from now)
Active
USRE46762
(Pediatric)
1′-substituted carba-nucleoside analogs for antiviral treatment 22 Oct, 2029
(4 years from now)
Active
US8008264 1′-substituted carba-nucleoside analogs for antiviral treatment 06 Sep, 2029
(4 years from now)
Active
US8318682 1′substituted carba-nucleoside analogs for antiviral treatment 22 Apr, 2029
(4 years from now)
Active
USRE46762 1′-substituted carba-nucleoside analogs for antiviral treatment 22 Apr, 2029
(4 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Veklury's drug page


14. Vemlidy

Vemlidy is protected by 7 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8754065
(Pediatric)
Tenofovir alafenamide hemifumarate 15 Feb, 2033
(8 years from now)
Active
US9296769
(Pediatric)
Tenofovir alafenamide hemifumarate 15 Feb, 2033
(8 years from now)
Active
US8754065 Tenofovir alafenamide hemifumarate 15 Aug, 2032
(7 years from now)
Active
US9296769 Tenofovir alafenamide hemifumarate 15 Aug, 2032
(7 years from now)
Active
US7390791
(Pediatric)
Prodrugs of phosphonate nucleotide analogues 17 Oct, 2025
(10 months from now)
Active
US7390791 Prodrugs of phosphonate nucleotide analogues 17 Apr, 2025
(4 months from now)
Active
US7803788 Prodrugs of phosphonate nucoleotide analogues 02 Feb, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vemlidy's drug page


15. Viread

Viread is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5922695
(Pediatric)
Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability 25 Jan, 2018
(6 years ago)
Expired
US5935946
(Pediatric)
Nucleotide analog composition and synthesis method 25 Jan, 2018
(6 years ago)
Expired
US5977089
(Pediatric)
Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jan, 2018
(6 years ago)
Expired
US6043230
(Pediatric)
Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jan, 2018
(6 years ago)
Expired
US5922695 Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability 25 Jul, 2017
(7 years ago)
Expired
US5935946 Nucleotide analog composition and synthesis method 25 Jul, 2017
(7 years ago)
Expired
US5977089 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jul, 2017
(7 years ago)
Expired
US6043230 Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability 25 Jul, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viread's drug page


16. Vitekta

Vitekta is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7635704
(Pediatric)
Stable crystal of 4-oxoquinoline compound 26 Apr, 2027
(2 years from now)
Active
US8981103
(Pediatric)
Stable crystal of 4-oxoquinoline compound 26 Apr, 2027
(2 years from now)
Active
US7176220
(Pediatric)
4-oxoquinoline compound and use thereof as pharmaceutical agent 27 Feb, 2027
(2 years from now)
Active
US7635704 Stable crystal of 4-oxoquinoline compound 26 Oct, 2026
(1 year, 11 months from now)
Active
US8981103 Stable crystal of 4-oxoquinoline compound 26 Oct, 2026
(1 year, 11 months from now)
Active
US7176220 4-oxoquinoline compound and use thereof as pharmaceutical agent 27 Aug, 2026
(1 year, 9 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vitekta's drug page


17. Vosevi

Vosevi is protected by 33 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11338007
(Pediatric)
Combination formulation of three antiviral compounds 01 Dec, 2037
(13 years from now)
Active
US10912814 Combination formulation of three antiviral compounds 01 Jun, 2037
(12 years from now)
Active
US11338007 Combination formulation of three antiviral compounds 01 Jun, 2037
(12 years from now)
Active
US11116783
(Pediatric)
Combination formulation of two antiviral compounds 30 Jul, 2034
(9 years from now)
Active
US9296782 Inhibitors of hepatitis C virus 17 Jul, 2034
(9 years from now)
Active
US11116783 Combination formulation of two antiviral compounds 30 Jan, 2034
(9 years from now)
Active
US8575135
(Pediatric)
Antiviral compounds 16 May, 2033
(8 years from now)
Active
US8921341
(Pediatric)
Antiviral compounds 16 May, 2033
(8 years from now)
Active
US8940718
(Pediatric)
Antiviral compounds 16 May, 2033
(8 years from now)
Active
US8575135 Antiviral compounds 16 Nov, 2032
(8 years from now)
Active
US8921341 Antiviral compounds 16 Nov, 2032
(8 years from now)
Active
US8940718 Antiviral compounds 16 Nov, 2032
(8 years from now)
Active
US9868745 Antiviral compounds 16 Nov, 2032
(8 years from now)
Active
US8618076
(Pediatric)
Nucleoside phosphoramidates 11 Jun, 2031
(6 years from now)
Active
US9284342
(Pediatric)
Nucleoside phosphoramidates 13 Mar, 2031
(6 years from now)
Active
US8618076 Nucleoside phosphoramidates 11 Dec, 2030
(6 years from now)
Active
US9284342 Nucleoside phosphoramidates 13 Sep, 2030
(5 years from now)
Active
US7964580
(Pediatric)
NA 26 Sep, 2029
(4 years from now)
Active
US8633309
(Pediatric)
Nucleoside phosphoramidates 26 Sep, 2029
(4 years from now)
Active
US8889159
(Pediatric)
Compositions and methods for treating hepatitis C virus 26 Sep, 2029
(4 years from now)
Active
US7964580 NA 26 Mar, 2029
(4 years from now)
Active
US8633309 Nucleoside phosphoramidates 26 Mar, 2029
(4 years from now)
Active
US8889159 Compositions and methods for treating hepatitis C virus 26 Mar, 2029
(4 years from now)
Active
US8334270
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US8580765
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US8735372
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US9085573
(Pediatric)
NA 21 Sep, 2028
(3 years from now)
Active
US8334270 NA 21 Mar, 2028
(3 years from now)
Active
US8580765 NA 21 Mar, 2028
(3 years from now)
Active
US8735372 NA 21 Mar, 2028
(3 years from now)
Active
US8957046 NA 21 Mar, 2028
(3 years from now)
Active
US9085573 NA 21 Mar, 2028
(3 years from now)
Active
US9585906 NA 21 Mar, 2028
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vosevi's drug page


18. Zydelig

Zydelig is protected by 13 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9469643 Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one 02 Sep, 2033
(8 years from now)
Active
US10730879 Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one 05 Mar, 2033
(8 years from now)
Active
US8865730 Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one 05 Mar, 2033
(8 years from now)
Active
US9492449 Therapies for hematologic malignancies 11 Mar, 2030
(5 years from now)
Active
USRE44638 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta 05 Aug, 2025
(8 months from now)
Active
USRE44599 Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta 21 Jul, 2025
(8 months from now)
Active
US8980901 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta 12 May, 2025
(5 months from now)
Active
US9149477 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta 12 May, 2025
(5 months from now)
Active
US6800620 Inhibitors of human phosphatidylinositol 3-kinase delta 24 Apr, 2021
(3 years ago)
Expired
US6949535 Inhibitors of human phosphatidyl-inositol 3-kinase delta 24 Apr, 2021
(3 years ago)
Expired
US8138195 Inhibitors of human phosphatidylinositol 3-kinase delta 24 Apr, 2021
(3 years ago)
Expired
US8492389 Inhibitors of human phosphatidylinositol 3-kinase delta 24 Apr, 2021
(3 years ago)
Expired
US8637533 Inhibitors of human phosphatidylinositol 3-kinase delta 24 Apr, 2021
(3 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zydelig's drug page


Gilead Sciences Inc News

Opposition from Indian patient groups to patent applications for lenacapavir, a popular HIV drug

18 Sep, 2024

The Indian Patent Office will consider challenges to Gilead's claims for a patent on an HIV drug

18 Sep, 2024

The Indian Patent Office will consider challenges to Gilead's patent claims for its HIV drug

17 Sep, 2024

Third Eye News reports on the projected size, share and forecast of the market for anti-HIV drugs in the United States for the year 2030.

16 Sep, 2024

See More